Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection

Journal of Clinical Virology

Volumn 57, Issue 4, 2013, Pages 356-360

  Choi, K Yeon ^a,c   Sharon, B ^a   Balfour, H H ^a   Belani, K ^b   Pozos, T C ^b   Schleiss, M R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Antiviral therapy; Congenital cytomegalovirus infection; Ganciclovir resistance; UL97 mutation

Indexed keywords

VALGANCICLOVIR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; INFANT; PERCEPTION DEAFNESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD; WILD TYPE;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY;

EID: 84879269504     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.04.004     Document Type: Article

References (38)

1. Jacobsen M.A., Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988, 108:585-594.
2. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006, 35:474-477.
3. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
4. Revello M.G., Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002, 15:680-715.
5. Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov 2007, 2:53-72.
6. Marshall B.C., Koch W.C. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs 2009, 11:309-321.
7. Andrei G., De Clercq E., Snoeck R. Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 2009, 9:201-222.
8. Sharland M., Luck S., Griffiths P., Cotton M. Antiviral therapy of CMV disease in children. Adv Exp Med Biol 2011, 697:243-260.
9. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965-981.
10. Freeman R.B. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. Expert Opin Pharmacother 2004, 5:2007-2016.
11. Torres-Madriz G., Boucher H.W. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008, 47:702-711.
12. Baldanti F., Lurain N., Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004, 65:403-409.
13. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23:689-712.
14. Schreiber A., Härter G., Schubert A., Bunjes D., Mertens T., Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009, 10:191-209.
15. Kimberlin D.W., Lin C.Y., Sánchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003, 143:16-25.
16. Oliver S.E., Cloud G.A., Sánchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009, 46:S22-S26.
17. Meine Jansen C.F., Toet M.C., Rademaker C.M., Ververs T.F., Gerards L.J., van Loon A.M. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 2005, 33:364-366.
18. Lombardi G., Garofoli F., Villani P., Tizzoni M., Angelini M., Cusato M., et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009, 28:1465-1470.
19. Amir J., Wolf D.G., Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010, 169:1061-1067.
20. Nassetta L., Kimberlin D., Whitley R. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother 2009, 63:862-867.
21. Blackman S.C., Lurain N.S., Witte D.P., Filipovich A.H., Groen P., Schleiss M.R. Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol 2004, 26:601-605.
22. Wolf D.G., Yaniv I., Honigman A., Kassis I., Schonfeld T., Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998, 178:535-538.
23. Campanini G., Zavattoni M., Cristina E., Gazzolo D., Stronati M., Baldanti F. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection. J Clin Virol 2012, 54:86-88.
24. Kampmann S.E., Schindele B., Apelt L., Bührer C., Garten L., Weizsaecker K., et al. Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol 2011, 200:109-113.
25. Müller A., Eis-Hübinger A.M., Brandhorst G., Heep A., Bartmann P., Franz A.R. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol 2008, 28:74-76.
26. Kimberlin D.W., Acosta E.P., Sánchez P.J., Sood S., Agrawal V., Homans J., et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008, 197:836-845.
27. Drew W.L., Miner R.C., Busch D.F., Follansbee S.E., Gullett J., Mehalko S.G., et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991, 163:716-719.
28. Boivin G., Goyette N., Rollag H., Jardine A.G., Pescovitz M.D., Asberg A., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14:697-704.
29. Martin M., Goyette N., Ives J., Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010, 47:321-324.
30. Emery V.C., Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000, 97:8039-8044.
31. Springer K.L., Chou S., Li S., Giller R.H., Quinones R., Shira J.E., Weinberg A. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005, 43:208-213.
32. Drew W.L., Liu C. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus. Clin Transplant 2012, 26:949-952.
33. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006, 16:281-287.
34. Chou S., Guentzel S., Michels K.R., Miner R.C., Drew W.L. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995, 172:239-242.
35. Gandhi R.S., Fernandez-Alvarez J.R., Rabe H. Management of congenital cytomegalovirus infection: an evidence-based approach. Acta Paediatr 2010, 99:509-515.
36. Drew W.L. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010, 50:733-736.
37. Daikoku T., Saito K., Aihara T., Ikeda M., Takahashi Y., Hosoi H., et al. Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. Microbiol Immunol 2013, 57:396-399.
38. Sedlak R.H., Castor J., Butler-Wu S.M., Chan E., Cook L., Limaye A.P., et al. Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples. J Clin Microbiol 2013, Epub ahead of print [PMID: 23678068].